Concurrent Stereotactic Radiosurgery and Bevacizumab in Recurrent Malignant Gliomas: A Prospective Trial

Journal Article · Thu Aug 01 04:00:00 EDT 2013 · International Journal of Radiation Oncology, Biology and Physics

DOI:https://doi.org/10.1016/J.IJROBP.2013.04.029· OSTI ID:22267830

Cabrera, Alvin R. ^[1]; Cuneo, Kyle C. ^[1]; Desjardins, Annick ^[2]; Sampson, John H. ^[1]; McSherry, Frances; Herndon, James E. ^[3]; Peters, Katherine B. ^[2]; Allen, Karen ^[1]; Hoang, Jenny K. ^[4]; Chang, Zheng; Craciunescu, Oana ^[1]; Vredenburgh, James J.; Friedman, Henry S. ^[2]

---

1. Department of Radiation Oncology, Duke University, Durham, North Carolina (United States)
2. Department of Surgery, Duke University, Durham, North Carolina (United States)
3. Department of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina (United States)
4. Department of Radiology, Duke University, Durham, North Carolina (United States)

Purpose: Virtually all patients with malignant glioma (MG) eventually recur. This study evaluates the safety of concurrent stereotactic radiosurgery (SRS) and bevacizumab (BVZ), an antiangiogenic agent, in treatment of recurrent MG. Methods and Materials: Fifteen patients with recurrent MG, treated at initial diagnosis with surgery and adjuvant radiation therapy/temozolomide and then at least 1 salvage chemotherapy regimen, were enrolled in this prospective trial. Lesions <3 cm in diameter were treated in a single fraction, whereas those 3 to 5 cm in diameter received 5 5-Gy fractions. BVZ was administered immediately before SRS and 2 weeks later. Neurocognitive testing (Mini-Mental Status Exam, Trail Making Test A/B), Functional Assessment of Cancer Therapy-Brain (FACT-Br) quality-of-life assessment, physical exam, and dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) were performed immediately before SRS and 1 week and 2 months following completion of SRS. The primary endpoint was central nervous system (CNS) toxicity. Secondary endpoints included survival, quality of life, microvascular properties as measured by DCE-MRI, steroid usage, and performance status. Results: One grade 3 (severe headache) and 2 grade 2 CNS toxicities were observed. No patients experienced grade 4 to 5 toxicity or intracranial hemorrhage. Neurocognition, quality of life, and Karnofsky performance status did not change significantly with treatment. DCE-MRI results suggest a significant decline in tumor perfusion and permeability 1 week after SRS and further decline by 2 months. Conclusions: Treatment of recurrent MG with concurrent SRS and BVZ was not associated with excessive toxicity in this prospective trial. A randomized trial of concurrent SRS/BVZ versus conventional salvage therapy is needed to establish the efficacy of this approach.

• OSTI ID: 22267830
• Journal Information: International Journal of Radiation Oncology, Biology and Physics, Journal Name: International Journal of Radiation Oncology, Biology and Physics Journal Issue: 5 Vol. 86; ISSN IOBPD3; ISSN 0360-3016
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
BRAIN
CHEMOTHERAPY
DIAGNOSIS
GLIOMAS
HEMORRHAGE
NMR IMAGING
PATIENTS
PERFORMANCE
RADIOTHERAPY
STEROIDS
SURGERY
TOXICITY